Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COOPERATE-II: everolimus with or without pasireotide LAR in advanced progressive pancreatic neuroendocrine tumors
NL-OMON38419Phase 2Active, not recruiting
- Sponsor
- Novartis
- Start
- Sep 2012
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in islet cell tumor comparing Everolimus alone with Everolimus + pasireotide LAR (2 arms). Primary endpoint: Progression-free survival. Started Sep 2012; status: active, not recruiting.
02
Drugs
everolimuspasireotide LAR
03
Conditions
islet cell tumor
Beyond the preview
Go deeper on NL-OMON38419.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON38419.